Join to view full profile
520 Country Club PkwyEugene, OR 97401
Phone+1 541-683-5001
Fax+1 541-683-1422
Dr. Butrynski is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 1998 - 1999
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1996 - 1998
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 1993 - 1996
Wayne State University School of MedicineClass of 1993
Certifications & Licensure
OR State Medical License 2017 - 2027
WA State Medical License 1998 - 2017
MA State Medical License 2007 - 2015
MD State Medical License 1996 - 1998
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2013-2017
Publications & Presentations
PubMed
- 34 citationsEfficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer.Alessandro D Santin, Bradley R Corr, Alexander Spira, Lyndsay Willmott, James Butrynski
Journal of Clinical Oncology. 2024-10-10 - Impact of an Oncology Clinical Pharmacist Intervention on Clinical Trial Enrollment in The US Oncology Network's MYLUNG Consortium.Elizabeth Koselke, Lisa C Kaspin-Powell, Shannon Hough, Joshua Howell, Nicholas J Robert
Journal of the Advanced Practitioner in Oncology. 2024-07-21 - 24 citationsResults of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung.Kristin Baird, John Glod, Seth M. Steinberg, Denise K. Reinke, Joseph G. Pressey
Sarcoma. 2020-04-30
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: